Aydın, O., Balıkçı, K., Taş, C., Ünal-Aydın, P., Taneli, F., Esen-Danacı, A., 2019. Assessing the relationship between attachment, parental attitude and plasma oxytocin in schizophrenia patients and their unaffected siblings. Nord J Psychiatry 73, 51-57.
Beckmann, H., Lang, R.E., Gattaz, W.F., 1985. Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 10, 187-191.
Churchland, P.S., Winkielman, P., 2012. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 61, 392-399.
Donadon, M.F., Martin-Santos, R., Osório, F.L., 2018. The Associations Between Oxytocin and Trauma in Humans: A Systematic Review. Front Pharmacol 9, 154.
Glovinsky, D., Kalogeras, K.T., Kirch, D.G., Suddath, R., Wyatt, R.J., 1994. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr Res 11, 273-276.
Goldman, M., Marlow-O'Connor, M., Torres, I., Carter, C.S., 2008. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 98, 247-255.
Guzel, D., Yazici, A.B., Pek, T.M., Doganay, S., Simsek, A.B.S., Saglam, K., Turan, C., Yazici, E., 2018. Atrial natriuretic peptide and posterior pituitary neurohormone changes in patients with acute schizophrenia. Neuropsychiatr Dis Treat 14, 1855-1860.
Jobst, A., Dehning, S., Ruf, S., Notz, T., Buchheim, A., Henning-Fast, K., Meißner, D., Meyer, S., Bondy, B., Müller, N., Zill, P., 2014. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr 26, 347-355.
Jones, C., Barrera, I., Brothers, S., Ring, R., Wahlestedt, C., 2017. Oxytocin and social functioning. Dialogues Clin Neurosci 19, 193-201.
Kéri, S., Kiss, I., Kelemen, O., 2009. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci 4, 287-293.
Liu, Y., Song, X., Liu, X., Pu, J., Gui, S., Xu, S., Tian, L., Zhong, X., Zhao, L., Wang, H., Liu, L., Xu, G., Xie, P., 2021. Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: a targeted metabolomics study. Psychiatry and clinical neurosciences.
Liu, Y., Tao, H., Yang, X., Huang, K., Zhang, X., Li, C., 2019. Decreased Serum Oxytocin and Increased Homocysteine in First-Episode Schizophrenia Patients. Front Psychiatry 10, 217.
Nadeem, Z., McIntosh, A., Lawrie, S., 2004. Schizophrenia. Evid Based Ment Health 7, 2-3.
Owen, M.J., Sawa, A., Mortensen, P.B., 2016. Schizophrenia. Lancet 388, 86-97.
Perkovic, M.N., Erjavec, G.N., Strac, D.S., Uzun, S., Kozumplik, O., Pivac, N., 2017. Theranostic Biomarkers for Schizophrenia. Int J Mol Sci 18.
Rubin, L.H., Carter, C.S., Bishop, J.R., Pournajafi-Nazarloo, H., Drogos, L.L., Hill, S.K., Ruocco, A.C., Keedy, S.K., Reilly, J.L., Keshavan, M.S., Pearlson, G.D., Tamminga, C.A., Gershon, E.S., Sweeney, J.A., 2014. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 40, 1374-1384.
Rubin, L.H., Carter, C.S., Bishop, J.R., Pournajafi-Nazarloo, H., Harris, M.S., Hill, S.K., Reilly, J.L., Sweeney, J.A., 2013. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr Res 146, 138-143.
Rubin, L.H., Carter, C.S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J.A., Maki, P.M., 2010. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 124, 13-21.
Rubin, L.H., Li, S., Yao, L., Keedy, S.K., Reilly, J.L., Hill, S.K., Bishop, J.R., Sue Carter, C., Pournajafi-Nazarloo, H., Drogos, L.L., Gershon, E., Pearlson, G.D., Tamminga, C.A., Clementz, B.A., Keshavan, M.S., Lui, S., Sweeney, J.A., 2018. Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia. Schizophr Res 202, 173-179.
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., Arima, K., Higuchi, T., Amano, N., Kunugi, H., 2012. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res 139, 201-206.
Schultz, S.H., North, S.W., Shields, C.G., 2007. Schizophrenia: a review. Am Fam Physician 75, 1821-1829.
Speck, L.G., Schöner, J., Bermpohl, F., Heinz, A., Gallinat, J., Majic, T., Montag, C., 2019. Endogenous oxytocin response to film scenes of attachment and loss is pronounced in schizophrenia. Soc Cogn Affect Neurosci 14, 109-117.
Stilo, S.A., Murray, R.M., 2019. Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep 21, 100.
Strauss, G.P., Chapman, H.C., Keller, W.R., Koenig, J.I., Gold, J.M., Carpenter, W.T., Buchanan, R.W., 2019. Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. J Psychiatr Res 112, 38-43.
Strauss, G.P., Keller, W.R., Koenig, J.I., Gold, J.M., Frost, K.H., Buchanan, R.W., 2015. Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr Res 162, 47-51.
Vargas, G., 2014. Biomarkers in schizophrenia. Biomark Med 8, 1-3.
Wahlberg, K.E., Wynne, L.C., Hakko, H., Läksy, K., Moring, J., Miettunen, J., Tienari, P., 2004. Interaction of genetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychol Med 34, 1531-1541.
Walss-Bass, C., Fernandes, J.M., Roberts, D.L., Service, H., Velligan, D., 2013. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr Res 147, 387-392.
Weickert, C.S., Weickert, T.W., Pillai, A., Buckley, P.F., 2013. Biomarkers in schizophrenia: a brief conceptual consideration. Dis Markers 35, 3-9.